PT-141 (10mg)

Cyclic melanocortin agonist (MC3R/MC4R) derived from Melanotan II. PT-141 is the deamidated metabolite of Melanotan II, developed after MT-II's sexual-response effect was noticed in early trials. It acts centrally through MC3R and MC4R rather than on blood flow, which distinguishes it from PDE5 inhibitors. As bremelanotide it is registered in the United States for hypoactive sexual desire disorder in premenopausal women.

Central arousal pathways: mC4R and dopamine interaction. Sexual-desire research: rECONNECT Phase 3 program. Non-vascular mechanisms: comparison with PDE5 inhibitors. Melanocortin pharmacology: relationship to MT-II. Phase 3 RECONNECT trials (Kingsberg et al., Obstet Gynecol 2019) reported increased sexual-desire scores versus placebo. Earlier trials in men with erectile dysfunction reported responses independent of nitric-oxide pathways.

RECONNECT Phase 3 trials reported increased sexual-desire scores and reduced distress versus placebo in premenopausal women; earlier studies in men reported erectile responses independent of nitric oxide.

Nausea was the most common event (around 40% in the Phase 3 trials), plus flushing, headache and transient blood-pressure increases; skin and gum darkening were reported with repeated use.

Published PT-141 studies specify their own amounts and routes, and those vary by model and endpoint. Peptide Aus products are supplied for in-vitro laboratory research, so we do not provide dosing, cycle or usage guidance for people. For laboratory preparation, the reconstitution calculator converts vial size and water volume into concentration and syringe units.

Bremelanotide was trialled as a nasal spray before the registered product became an injection. Sprays sold online are unverified; Peptide Aus supplies the 10mg vial for research.

PT-141 is the deamidated metabolite of MT-II, keeping the central sexual-response effect.

PDE5 inhibitors act on blood flow; PT-141 acts centrally on melanocortin receptors.

Add about 2 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 10mg in 2 mL gives 5 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

Bremelanotide is registered in the United States but not by the TGA, so there is no approved PT-141 product in Australia. Peptide Aus supplies research-grade PT-141 for in-vitro laboratory use only.

Directly from Peptide Aus, from Australian stock: PT-141 (10mg) is $99.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.